​

Integra LifeSciences (IART) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IART Stock Forecast

Integra LifeSciences (IART) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $43.00, with a high of $86.00 and a low of $20.00. This represents a 171.64% increase from the last price of $15.83.

$15 $30 $45 $60 $75 $90 High: $86 Avg: $43 Low: $20 Last Closed Price: $15.83

IART Stock Rating

Integra LifeSciences stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (54.55%), 7 Hold (31.82%), 3 Sell (13.64%), and 0 Strong Sell (0.00%).

Buy
Total 22 3 7 12 0 Strong Sell Sell Hold Buy Strong Buy

IART Price Target Upside V Benchmarks

TypeNameUpside
StockIntegra LifeSciences171.64%
SectorHealthcare Stocks 35.25%
IndustryMedical Device Stocks21.20%

Price Target Trends

1M3M12M
# Anlaysts--8
Avg Price Target--$26.63
Last Closing Price$15.83$15.83$15.83
Upside/Downside--68.22%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 251252212
Mar, 251162212
Feb, 251162212
Jan, 251162212
Dec, 242162213
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 07, 2024Ryan ZimmermanBTIG$20.00$17.4314.74%26.34%
Jul 30, 2024Richard NewitterTruist Financial$26.00$24.595.73%64.25%
Jul 30, 2024Joanne WuenschCitigroup$23.00$25.42-9.52%45.29%
Jul 29, 2024Ryan ZimmermanBTIG$22.00$25.42-13.45%38.98%
Jul 16, 2024Richard NewitterTruist Financial$32.00$29.847.24%102.15%
May 07, 2024Richard NewitterTruist Financial$25.00$23.148.04%57.93%
May 07, 2024David TurkalyJMP Securities$40.00$23.1472.86%152.68%
May 06, 2024Vik ChopraWells Fargo$25.00$23.148.04%57.93%
Oct 26, 2022Matt O'BrienPiper Sandler$50.00$46.856.72%215.86%
Jul 28, 2022FY22 EPSPiper Sandler$55.00$56.53-2.71%247.44%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 04, 2024CitigroupSellSellhold
Jul 30, 2024JMP SecuritiesMarket OutperformMarket Outperformhold
Jul 30, 2024CitigroupNeutralSelldowngrade
Jul 29, 2024BTIGSellNegativedowngrade
Jul 29, 2024BTIGSelldowngrade
Jul 15, 2024Morgan StanleyUnderweightUnderweighthold
Jul 10, 2024CitigroupNeutralNeutralhold
May 22, 2024CitigroupNeutralNeutralhold
May 07, 2024Wells FargoMarket OutperformMarket Outperformhold
May 07, 2024JMP SecuritiesOutperformOutperformhold

Financial Forecast

EPS Forecast

$-1 $0 $1 $2 $3 $4 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$1.58$2.00$2.18$0.87$-0.09---
Avg Forecast$2.35$3.18$3.31$3.11$2.45$2.51$2.78$3.38
High Forecast$2.38$3.21$3.33$3.12$2.47$2.60$3.64$3.40
Low Forecast$2.33$3.14$3.29$3.08$2.43$2.43$1.75$3.35
Surprise %-32.77%-37.11%-34.14%-72.03%-103.67%---

Revenue Forecast

$1B $1B $2B $2B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$1.37B$1.54B$1.56B$1.54B$1.61B---
Avg Forecast$1.37B$1.54B$1.56B$1.54B$1.61B$1.71B$1.79B$1.94B
High Forecast$1.38B$1.55B$1.56B$1.55B$1.62B$1.72B$1.79B$1.95B
Low Forecast$1.36B$1.53B$1.55B$1.53B$1.60B$1.70B$1.79B$1.93B
Surprise %-0.03%0.14%-0.03%-0.16%-0.17%---

Net Income Forecast

$-50M $20M $90M $160M $230M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$133.89M$169.07M$180.55M$67.74M$-6.94M---
Avg Forecast$108.10M$144.29M$161.85M$67.74M$196.95M$202.38M$216.78M$271.54M
High Forecast$129.91M$173.14M$194.22M$81.29M$198.56M$209.25M$292.79M$273.45M
Low Forecast$86.29M$115.43M$129.48M$54.19M$195.34M$195.52M$140.76M$269.14M
Surprise %23.86%17.18%11.55%--103.53%---

IART Forecast FAQ

Is Integra LifeSciences stock a buy?

Integra LifeSciences stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 7 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Integra LifeSciences is a favorable investment for most analysts.

What is Integra LifeSciences's price target?

Integra LifeSciences's price target, set by 22 Wall Street analysts, averages $43 over the next 12 months. The price target range spans from $20 at the low end to $86 at the high end, suggesting a potential 171.64% change from the previous closing price of $15.83.

How does Integra LifeSciences stock forecast compare to its benchmarks?

Integra LifeSciences's stock forecast shows a 171.64% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the medical device stocks industry (21.20%).

What is the breakdown of analyst ratings for Integra LifeSciences over the past three months?

  • April 2025: 8.33% Strong Buy, 16.67% Buy, 41.67% Hold, 16.67% Sell, 16.67% Strong Sell.
  • March 2025: 8.33% Strong Buy, 8.33% Buy, 50.00% Hold, 16.67% Sell, 16.67% Strong Sell.
  • February 2025: 8.33% Strong Buy, 8.33% Buy, 50.00% Hold, 16.67% Sell, 16.67% Strong Sell.

What is Integra LifeSciences’s EPS forecast?

Integra LifeSciences's average annual EPS forecast for its fiscal year ending in December 2025 is $2.51, marking a -2888.89% decrease from the reported $-0.09 in 2024. Estimates for the following years are $2.78 in 2026, and $3.38 in 2027.

What is Integra LifeSciences’s revenue forecast?

Integra LifeSciences's average annual revenue forecast for its fiscal year ending in December 2025 is $1.71B, reflecting a 6.33% increase from the reported $1.61B in 2024. The forecast for 2026 is $1.79B, and $1.94B for 2027.

What is Integra LifeSciences’s net income forecast?

Integra LifeSciences's net income forecast for the fiscal year ending in December 2025 stands at $202.38M, representing a -3014.51% decrease from the reported $-6.944M in 2024. Projections indicate $216.78M in 2026, and $271.54M in 2027.